Delivery Order SPE2DB22D2206-SPE2DB25FHY97
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,305.23 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (30-count) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order represents a non-set-aside competitively awarded contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $10,844.61 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order, which is not set-aside, represents a single pharmaceutical procurement under the company's broader contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,099.74 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count packages) on July 24, 2025, with completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,957.32 to AmerisourceBergen Drug Corp for Jardiance 10 mg tablets (90-count units) on August 10, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, serves the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,146.61 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is performing this order from its corporate office location in the same...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,813.72 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract contains no set-aside provisions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,431.84 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count) on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of DLA's pharmaceutical procurement operations. The contract's place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $6,732.17 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count) on July 25, 2025, with completion scheduled for July 28, 2025. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $15,404.48 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-competitive delivery order utilizes firm fixed pricing and is sourced from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement to support federal healthcare operations....
- The Defense Logistics Agency awarded a $12.5K firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract represents a routine pharmaceutical procurement fulfilling federal medical supply needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the Defense...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHY97Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,128.61 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets in a 90-count quantity. Issued on July 18, 2025, with an ultimate completion date of July 21, 2025, this firm fixed-price contract represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical commodities to support military healthcare programs worldwide. The DLA's Pharmaceutical Prime Vendor Global Program represents a strategic approach to pharmaceutical procurement, with plans for multiple regional contract awards to ensure sustained access to critical medications and medical supplies for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.1k | 7/18/25 |